Key facts
- NeuroThree Therapeutics’s last known valuation is $33.5M (Mar 2025).
- It has raised $13.5M; the latest was Early Stage VC ($3.5M) in Mar 2025.
- Notable investors include Qiming Venture Partners, Jiangsu Nhwa Pharmaceutical Company, K2 Venture Finance.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for NeuroThree Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroThree Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroThree Therapeutics
Provider of innovative therapies designed for central nervous system disorders. The company focuses on pioneering treatments for neurological conditions, providing transformative solutions for excitatory and neurodegenerative diseases through advanced drug research and clinical trials.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Website
- neuro3therapeutics.com/
- Ownership
- Privately Held (backing)
NeuroThree Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroThree Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroThree Therapeutics in its N-PORT filings yet. We sweep new filings monthly.